Athira Pharma acquired exclusive global rights for the development and commercialization of lasofoxifene, a selective estrogen receptor modulator (SERM) for metastatic breast cancer.
The Phase 3 ELAINE-3 clinical trial is over 50% enrolled, with data expected in mid-2027.
The company secured an upfront financing of $90 million with potential additional funding from warrants reaching up to $146 million.
Program Acquisition
Athira acquired the rights for the Phase 3 lasofoxifene program for metastatic breast cancer, showing commitment to developing innovative therapies.
Financial Support
The financing of $90 million, co-led by Commodore Capital, Perceptive Advisors, and TCGX, will fund the development of lasofoxifene through key clinical milestones.
Clinical Impact
Lasofoxifene demonstrated promising efficacy in Phase 2 trials, potentially offering a new standard of care for ESR1-mutant breast cancer patients.
- The acquisition of the lasofoxifene development program represents a significant strategic move for Athira Pharma, positioning them to address high unmet medical needs in metastatic breast cancer treatment.
- The financial support from key investors highlights confidence in Athira's development strategy and the potential of lasofoxifene to make a meaningful impact in the oncology field.
Athira Pharma's entry into the Phase 3 development of lasofoxifene signifies a crucial step towards advancing innovative therapies for metastatic breast cancer. With strong financial backing and promising clinical data, Athira is poised to make a meaningful impact in the field of oncology.